Table 4.

Characteristics of participants that became seronegative at five to six months after the second dose.

Diagnosis n (%)	Ongoing therapy	Age mean ± SD (range)	Gender n (%)	Vaccine n (%)
SOT: 4 (21.0) [lung cancer: 2 (10.5); breast cancer: 2 (10.5)]	antimetabolites, alkylating agents, anti-PD-1, mitotic inhibitors, hormones, steroids	70.3 ± 11; (52 - 81)	Female:4 (100), male:(0)	BNT162b2: 3 (75), mRNA-1273: 1 (25)
MM: 11 (57.9) (of those 6 with stem cell transplantation)	thalidomide analogue, proteasome inhibitor, steroids, anti-CD38; n=3 without ongoing treatment	66.5 ± 7.3; (57 - 80)	Female:3 (27.3), Male: 8 (72,7)	BNT162b2:7 (63.6), mRNA-1273: 4 (36.4)
IBD: 4 (21.1) [CD 3 (15.8); UC 1 (5.3)]	thiopurins, TNF-α inhibitors, steroids	47.5 ± 14; (31 - 68)	Female: 1 (25), male: 3 (75)	BNT162b2: 0, mRNA-1273: 4 (100)

Clinical and demographic parameters of those 19 patients with negative antibody responses measured at five-six months after the second vaccine dose.